PMID- 25666221 OWN - NLM STAT- MEDLINE DCOM- 20160308 LR - 20220309 IS - 1525-1497 (Electronic) IS - 0884-8734 (Print) IS - 0884-8734 (Linking) VI - 30 IP - 6 DP - 2015 Jun TI - A Randomized Controlled Effectiveness Trial for PSA Screening Decision Support Interventions in Two Primary Care Settings. PG - 810-6 LID - 10.1007/s11606-015-3214-9 [doi] AB - BACKGROUND: Decision support interventions (DESIs) provide a mechanism to translate comparative effectiveness research results into clinical care so that patients are able to make informed decisions. Patient decision support interventions for prostate-specific antigen (PSA) have been shown to promote informed decision making and reduce PSA testing in efficacy trials, but their impact in real world settings is not clear. OBJECTIVE: We performed an effectiveness trial of PSA decision support interventions in primary care. DESIGN: A randomized controlled trial of three distribution strategies was compared to a control. PARTICIPANTS: Participants included 2,550 men eligible for PSA testing (76.6 % of the eligible population) and 2001 survey respondents (60.1 % survey response rate). INTERVENTIONS: The intervention groups were: 1) mailed the DESI in DVD format, 2) offered a shared medical appointment (SMA) to view the DESI with other men and discuss, and 3) both options. MAIN MEASURES: We measured PSA testing identified via electronic medical record at 12 months and DESI use by self-report 4 months after the intervention mailing. KEY RESULTS: We found no differences in PSA testing across the three distribution strategies over a year-long follow-up period: 21 %, 24 %, 22 % in the DESI, SMA, and combined group respectively, compared to 21 % in the control group (p = 0.51). Self-reported DESI use was low across all strategies at 4 months: 16 % in the mailed DESI group, 6 % in the SMA group, and 15 % in the combined group (p = < 0.0001). CONCLUSIONS: Mailing PSA decision support interventions or inviting men to shared medical appointments unrelated to a primary care office visit do not appear to promote informed decision making, or change PSA testing behavior. FAU - Lewis, Carmen L AU - Lewis CL AD - Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Mail stop B180, Academic Office 1, Room 8415, 12631 E 17th Ave, Aurora, CO, 80045, USA, Carmen.L.Lewis@ucdenver.edu. FAU - Adams, Jared AU - Adams J FAU - Tai-Seale, Ming AU - Tai-Seale M FAU - Huang, Qiwen AU - Huang Q FAU - Knowles, Sarah B AU - Knowles SB FAU - Nielsen, Matthew E AU - Nielsen ME FAU - Pignone, Michael P AU - Pignone MP FAU - Walter, Louise C AU - Walter LC FAU - Frosch, Dominick L AU - Frosch DL LA - eng SI - ClinicalTrials.gov/NCT01241656 GR - K24 AG041180/AG/NIA NIH HHS/United States GR - R01 CA134425/CA/NCI NIH HHS/United States GR - R01 CA1334425-01/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. DEP - 20150210 PL - United States TA - J Gen Intern Med JT - Journal of general internal medicine JID - 8605834 RN - EC 3.4.21.- (KLK3 protein, human) RN - EC 3.4.21.- (Kallikreins) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM CIN - Evid Based Med. 2015 Aug;20(4):139. PMID: 26041793 MH - Aged MH - *Decision Support Techniques MH - Early Detection of Cancer/methods MH - Humans MH - Kallikreins/*blood MH - Male MH - Middle Aged MH - *Primary Health Care MH - Prostate-Specific Antigen/*blood MH - Prostatic Neoplasms/*diagnosis PMC - PMC4441669 EDAT- 2015/02/11 06:00 MHDA- 2016/03/10 06:00 PMCR- 2016/06/01 CRDT- 2015/02/11 06:00 PHST- 2014/08/20 00:00 [received] PHST- 2015/01/23 00:00 [accepted] PHST- 2015/01/12 00:00 [revised] PHST- 2015/02/11 06:00 [entrez] PHST- 2015/02/11 06:00 [pubmed] PHST- 2016/03/10 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 3214 [pii] AID - 10.1007/s11606-015-3214-9 [doi] PST - ppublish SO - J Gen Intern Med. 2015 Jun;30(6):810-6. doi: 10.1007/s11606-015-3214-9. Epub 2015 Feb 10.